Evidence map›Paper›PMID 40667050›Full record

ArticlebioRxiv : the preprint server for biology2025

A Human Tumor-Immune Organoid Model of Glioblastoma.

Shivani Baisiwala, Elisa Fazzari, Matthew X Li, Antoni Martija, Daria J Azizad, Lu Sun, Gilbert Herrera, Trinh Phan, Amber Monteleone, David A Nathanson and 7 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

Shivani BaisiwalaDepartment of Neurosurgery, UCLA Health, Los Angeles, CA, USA.ORCID 0000-0001-5252-9940
Elisa FazzariDepartment of Biological Chemistry, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.ORCID 0000-0001-5651-8587
Matthew X LiDepartment of Biological Chemistry, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.ORCID 0009-0009-0539-7389
Antoni MartijaDepartment of Biological Chemistry, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.ORCID 0000-0003-4293-6002
Daria J AzizadDepartment of Biological Chemistry, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.ORCID 0009-0006-7015-9027
Lu SunDepartment of Neurosurgery, UCLA Health, Los Angeles, CA, USA.ORCID 0000-0002-6592-1156
Gilbert HerreraDepartment of Neurosurgery, UCLA Health, Los Angeles, CA, USA.
Trinh PhanDepartment of Neurosurgery, UCLA Health, Los Angeles, CA, USA.
Amber MonteleoneDepartment of Neurosurgery, UCLA Health, Los Angeles, CA, USA.
David A NathansonDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles, CA, USA.
Anthony WangDepartment of Neurosurgery, UCLA Health, Los Angeles, CA, USA.ORCID 0000-0002-9509-6257
Won KimDepartment of Neurosurgery, UCLA Health, Los Angeles, CA, USA.ORCID 0000-0003-3423-3825
Richard G EversonDepartment of Neurosurgery, UCLA Health, Los Angeles, CA, USA.ORCID 0000-0003-2809-3061
Kunal S PatelDepartment of Neurosurgery, UCLA Health, Los Angeles, CA, USA.ORCID 0000-0002-9854-9178
Linda M LiauDepartment of Neurosurgery, UCLA Health, Los Angeles, CA, USA.ORCID 0000-0002-4053-0052
Robert M PrinsDepartment of Neurosurgery, UCLA Health, Los Angeles, CA, USA.ORCID 0000-0002-6282-6583
Aparna BhaduriDepartment of Biological Chemistry, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.ORCID 0000-0003-4625-6899

Funding

UCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Yvonne Yu-Hsuan Chen · 2017 to 2026
$25.2M
UCLA-Caltech Medical Scientist Training ProgramT32GM152342 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Olujimi A Ajijola, David Wayne Dawson · 2024 to 2026
$5.3M
NCI NIH HHS P50 CA211015NIGMS NIH HHS T32 GM152342
6 · The paper itself

Abstract

A major obstacle to identifying effective therapies for the aggressive brain tumor glioblastoma is the lack of human-specific, immunocompetent models that reflect the human tumor microenvironment. To address this, we developed the immune-Human Organoid Tumor Transplantation (iHOTT) model. This is an autologous co-culture platform that integrates patient-derived tumor cells and matched peripheral blood mononuclear cells (PBMCs) within human cortical organoids, enabling the study of the patient-specific immune response to the tumor and tumor-immune interactions. This platform preserves tumor and immune populations, immune signaling, and cell-cell interactions observed in patient tumors. Treatment of iHOTT with pembrolizumab, a checkpoint inhibitor, mirrored cell type shifts and cell interactions observed in patients. TCR sequencing further revealed pembrolizumab-driven expansion of stem-like CD4-T-cell clonotypes exhibiting patient-specific repertoires. These findings establish iHOTT as a physiologically relevant platform for exploring autologous tumor-immune interactions and underscore the critical need for antigen-targeted strategies to enhance immunotherapy in glioblastoma.

Identifiers

PMID40667050
PMCPMC12262450

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.